1. Home
  2. NVTS vs MESO Comparison

NVTS vs MESO Comparison

Compare NVTS & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Navitas Semiconductor Corporation

NVTS

Navitas Semiconductor Corporation

HOLD

Current Price

$14.82

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$15.24

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVTS
MESO
Founded
2014
2004
Country
United States
Australia
Employees
N/A
81
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.1B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
NVTS
MESO
Price
$14.82
$15.24
Analyst Decision
Buy
Strong Buy
Analyst Count
5
1
Target Price
$6.68
N/A
AVG Volume (30 Days)
28.8M
203.3K
Earning Date
05-05-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$45,916,000.00
N/A
Revenue This Year
N/A
$629.74
Revenue Next Year
$71.28
$30.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.80
$9.88
52 Week High
$19.79
$21.50

Technical Indicators

Market Signals
Indicator
NVTS
MESO
Relative Strength Index (RSI) 59.25 48.19
Support Level $7.05 $14.44
Resistance Level $17.79 $16.49
Average True Range (ATR) 1.60 0.43
MACD 0.58 0.01
Stochastic Oscillator 54.31 39.08

Price Performance

Historical Comparison
NVTS
MESO

About NVTS Navitas Semiconductor Corporation

Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components. Geographically, the company operates in Hong Kong, China, Europe, the United States, Rest of Asia, and Others. The majority of revenue is generated from Hong Kong.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: